Takeda Pharmaceutical Reports Positive Phase 3 Data for Zasocitinib in Moderate-to-Severe Plaque Psoriasis

MT Newswires Live07-17

Takeda Pharmaceutical (TAK) said late Thursday that new phase 3 data showed its oral TYK2 inhibitor, zasocitinib, delivered high rates of skin clearance across difficult-to-treat body sites in adults with moderate-to-severe plaque psoriasis.

The company said about 75% of patients with scalp psoriasis and about 70% of those with palmoplantar psoriasis achieved clear or almost clear skin at week 16.

Zasocitinib also significantly improved Nail Psoriasis Severity Index scores versus placebo, with responses maintained through week 24 and no new safety signals observed, the company added.

Takeda said it plans to begin regulatory filings for zasocitinib in plaque psoriasis with the US Food and Drug Administration and other health authorities this fiscal year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2652405308?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-17 16:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2652405308","market":"nz","top_or_hot":-1,"title":"Takeda Pharmaceutical Reports Positive Phase 3 Data for Zasocitinib in Moderate-to-Severe Plaque Psoriasis","media":"MT Newswires Live","content":"<html><body><p> Takeda Pharmaceutical (TAK) said late Thursday that new phase 3 data showed its oral TYK2 inhibitor, zasocitinib, delivered high rates of skin clearance across difficult-to-treat body sites in adults with moderate-to-severe plaque psoriasis.</p><p>The company said about 75% of patients with scalp psoriasis and about 70% of those with palmoplantar psoriasis achieved clear or almost clear skin at week 16.</p><p>Zasocitinib also significantly improved Nail Psoriasis Severity Index scores versus placebo, with responses maintained through week 24 and no new safety signals observed, the company added.</p><p>Takeda said it plans to begin regulatory filings for zasocitinib in plaque psoriasis with the US Food and Drug Administration and other health authorities this fiscal year.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Takeda Pharmaceutical Reports Positive Phase 3 Data for Zasocitinib in Moderate-to-Severe Plaque Psoriasis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTakeda Pharmaceutical Reports Positive Phase 3 Data for Zasocitinib in Moderate-to-Severe Plaque Psoriasis\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-17 16:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Takeda Pharmaceutical (TAK) said late Thursday that new phase 3 data showed its oral TYK2 inhibitor, zasocitinib, delivered high rates of skin clearance across difficult-to-treat body sites in adults with moderate-to-severe plaque psoriasis.</p><p>The company said about 75% of patients with scalp psoriasis and about 70% of those with palmoplantar psoriasis achieved clear or almost clear skin at week 16.</p><p>Zasocitinib also significantly improved Nail Psoriasis Severity Index scores versus placebo, with responses maintained through week 24 and no new safety signals observed, the company added.</p><p>Takeda said it plans to begin regulatory filings for zasocitinib in plaque psoriasis with the US Food and Drug Administration and other health authorities this fiscal year.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TAK","symbol_name":"武田制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2652405308","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2652405308","pubTimestamp":1784276511,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Takeda Pharmaceutical  said late Thursday that new phase 3 data showed its oral TYK2 inhibitor, zasocitinib, delivered high rates of skin clearance across difficult-to-treat body sites in adults with moderate-to-severe plaque psoriasis.The company said about 75% of patients with scalp psoriasis and about 70% of those with palmoplantar psoriasis achieved clear or almost clear skin at week 16.Zasocitinib also significantly improved Nail Psoriasis Severity Index scores versus placebo, with responses maintained through week 24 and no new safety signals observed, the company added.Takeda said it plans to begin regulatory filings for zasocitinib in plaque psoriasis with the US Food and Drug Administration and other health authorities this fiscal year.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TAK":"武田制药","BK4007":"制药"},"translate_title":"武田制药报告Zasocitinib治疗中重度斑块状银屑病的积极3期数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TAK":1},"content_text":"Takeda Pharmaceutical (TAK) said late Thursday that new phase 3 data showed its oral TYK2 inhibitor, zasocitinib, delivered high rates of skin clearance across difficult-to-treat body sites in adults with moderate-to-severe plaque psoriasis.The company said about 75% of patients with scalp psoriasis and about 70% of those with palmoplantar psoriasis achieved clear or almost clear skin at week 16.Zasocitinib also significantly improved Nail Psoriasis Severity Index scores versus placebo, with responses maintained through week 24 and no new safety signals observed, the company added.Takeda said it plans to begin regulatory filings for zasocitinib in plaque psoriasis with the US Food and Drug Administration and other health authorities this fiscal year.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2652405308","isCrawlerRequest":true}